All In Biotech

Drug Trial Radar · NCT06308393

Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects With Psoriasis

Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

98

Actual

Start

Mar 1, 2024

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, double-blind, placebo-controlled study of RSS0393 ointment in healthy and psoriatic subjects

Conditions

  • Healthy
  • Psoriatic Subjects

Interventions

  • RSS0393 ointment;PlaceboDrug

    RSS0393 ointment;RSS0393 ointment placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percent of Local skin tolerance was assessed as moderate or higher(Single dose in healthy subjects)Time frame: 0.5, 2, 4, 12 post -dose day 1, day 2, day 3, day 5, and day 8
  2. The percent of Local skin tolerance was assessed as moderate or higher (Multiple dose in healthy subjects)Time frame: 0.5, 2, 4, 12 post-dose day 1, 0.5post-dose on day2、day3、day4、day5、day6, 0.5, 2, 4, 12 post-dose day7, day8, day9, day11, day14
  3. Measurement of blood examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
  4. Measurement of urine examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
  5. Measurement of Blood Chemistry examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
  6. Measurement of coagulation function examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China (USTC).

    Hefei, Anhui, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.